AzaCITIDine

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11081 publications

Exploring the Neuroprotective Potential of 5-Azacytidine on the Streptozotocin-Induced Rat Model of Alzheimer's Disease.

Exploring the Neuroprotective Potential of 5-Azacytidine on the Streptozotocin-Induced Rat Model of Alzheimer's Disease.

Journal: ACS chemical neuroscience

Published: June 22, 2026

Tetrahydrouridine pretreatment increases tissue exposure of 14C-decitabine in mice.

Tetrahydrouridine pretreatment increases tissue exposure of 14C-decitabine in mice.

Journal: Xenobiotica; the fate of foreign compounds in biological systems

Published: June 18, 2026

Tetrahydrouridine pre-treatment increases tissue exposure of 14C-decitabine in mice.

Tetrahydrouridine pre-treatment increases tissue exposure of 14C-decitabine in mice.

Journal: Xenobiotica; the fate of foreign compounds in biological systems

Published: June 18, 2026

Arginine metabolism supports de novo pyrimidine biosynthesis to block DNA damage and maintain Epstein-Barr virus latency.

Arginine metabolism supports de novo pyrimidine biosynthesis to block DNA damage and maintain Epstein-Barr virus latency.

Journal: mBio

Published: June 15, 2026

Structural and cellular insights into DCTPP1 antagonists and their synergistic action with DNMT inhibitors.

Structural and cellular insights into DCTPP1 antagonists and their synergistic action with DNMT inhibitors.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: June 15, 2026

Role of exogenous supplementation of umbilical cord blood immune cells in reconstructing immune function and restoring hematopoietic function in elderly high-risk myeloid neoplasms patients

Role of exogenous supplementation of umbilical cord blood immune cells in reconstructing immune function and restoring hematopoietic function in elderly high-risk myeloid neoplasms patients

Journal: Zhonghua yi xue za zhi

Published: June 15, 2026

Management of Acute Myeloid Leukemia in a Dialysis-Dependent Patient: A Case Report, Literature Review, and Therapeutic Considerations.

Management of Acute Myeloid Leukemia in a Dialysis-Dependent Patient: A Case Report, Literature Review, and Therapeutic Considerations.

Journal: Cureus

Published: June 12, 2026

The All-Oral Combination of Revumenib, Decitabine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (SAVE).

The All-Oral Combination of Revumenib, Decitabine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (SAVE).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 11, 2026

Bone marrow endothelial injury by venetoclax and azacitidine.

Bone marrow endothelial injury by venetoclax and azacitidine.

Journal: Blood

Published: June 11, 2026

Strand-specific quantification of L1 ORF0 and related transcripts by multiplex reverse transcription with tagged primers.

Strand-specific quantification of L1 ORF0 and related transcripts by multiplex reverse transcription with tagged primers.

Journal: BioTechniques

Published: June 08, 2026

All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia.

All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia.

Journal: The New England journal of medicine

Published: June 03, 2026

Pharmacology-Guided venetoclax dose reduction with azacitidine in older or unfit acute myeloid leukemia: A North African experience from a Moroccan single-center cohort and exploratory hospital cost-effectiveness analysis.

Pharmacology-Guided venetoclax dose reduction with azacitidine in older or unfit acute myeloid leukemia: A North African experience from a Moroccan single-center cohort and exploratory hospital cost-effectiveness analysis.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: June 02, 2026

Showing 1-12 of 11,081

Last Updated: 06/30/2026